Evidence map›Paper›PMID 42815008›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2026

Identification of benzoxazine scaffold derivatives as novel CDK4 inhibitors for the treatment of cancer.

Chao Lin, Shaofeng Sun, Huateng Zhang, Dan Yang, Youyan Wei, Bo Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chao LinDepartment Traditional Chinese Medicine, Shandong College of Traditional Chinese Medicine, Yantai, Shandong, China.
Shaofeng SunYantai Key Laboratory of Nanomedicine and Advanced Preparations, Yantai Institute of Materia Medica, Yantai, Shandong, China.
Huateng ZhangDepartment Traditional Chinese Medicine, Shandong College of Traditional Chinese Medicine, Yantai, Shandong, China.
Dan YangDepartment Traditional Chinese Medicine, Shandong College of Traditional Chinese Medicine, Yantai, Shandong, China.
Youyan WeiShandong Luye Pharmaceutical Co. Ltd, Yantai, China.
Bo LiDepartment Traditional Chinese Medicine, Shandong College of Traditional Chinese Medicine, Yantai, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclin-dependent kinase 4, a pivotal regulator of cell cycle progression, is widely recognised as a therapeutic target for controlling tumour proliferation. Inspired by the reported CDK4 inhibitor PF-07220060, a series of novel benzoxazine derivatives were designed, synthesised, and evaluated for their biological activity. From this series, compound

Indexed as

Antineoplastic AgentsBenzoxazinesCyclin-Dependent Kinase 4Protein Kinase InhibitorsApoptosisCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsBenzoxazinesCDK4 protein, humanCyclin-Dependent Kinase 4Protein Kinase InhibitorsbenzoxazinecancerCDK4

Identifiers

PMID42815008
PMCPMC13629794

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.